American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

Cardiology, cardiac imaging groups support new bill delaying cuts to physician pay
Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.
TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update
The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.
Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning
Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive.
Ultrathin iron bioresorbable scaffold shows promise in first randomized trial
An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC.
Boston EP Party: Medtech companies share new electrophysiology data at AF Symposium 2026
AF Symposium 2026 in Boston included new data from some of the biggest names in electrophysiology. Johnson & Johnson MedTech, Abbott, Atraverse Medical, Field Medical, Pulse Biosciences, Argá Medtech SA and CardioFocus were just some of the medtech companies at the heart of late-breaking presentations.

money cost cutting Medicare scissors dollar economics

Cardiology, cardiac imaging groups support new bill delaying cuts to physician pay

Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.

Medtronic's Evolut Pro TAVR valve treating aortic stenosis

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive.

iron bioresorbable scaffold Biotyx Medical

Ultrathin iron bioresorbable scaffold shows promise in first randomized trial

An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC.

Boston EP Party: Medtech companies share new electrophysiology data at AF Symposium 2026

AF Symposium 2026 in Boston included new data from some of the biggest names in electrophysiology. Johnson & Johnson MedTech, Abbott, Atraverse Medical, Field Medical, Pulse Biosciences, Argá Medtech SA and CardioFocus were just some of the medtech companies at the heart of late-breaking presentations.

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

SAVR linked to ‘excellent’ long-term survival for patients with bicuspid aortic valves

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.

IVL may be safer than atherectomy in patients with severely calcified lesions

Researchers explored data from more than 1,000 patients with calcified coronary artery disease who required plaque modification. IVL and atherectomy were linked to comparable success rates, but adverse events were less likely with IVL.